

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Gladwin *et al.*

**Application No.** 10/563,682

**Filed:** January 6, 2006

**Confirmation No.** 3411

**For:** USE OF NITRITE SALTS FOR THE  
TREATMENT OF CARDIOVASCULAR  
CONDITIONS

**FILED VIA EFS**

**Examiner:** Ernst V. Arnold

**Art Unit:** 1616

**Attorney Reference No.** 4239-67618-05

SUBMITTED VIA ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

**AMENDMENT AND RESPONSE AFTER FINAL ACTION**  
**SUBMITTED WITH A REQUEST FOR CONTINUED EXAMINATION (RCE)**

This responds to the final Office action dated January 6, 2009, and the Advisory Action dated April 2, 2009. A three-month period for reply to the final Office act was set, making a response due on or before April 6, 2009. Applicants request a three-month extension and submit the corresponding fee herewith, making a response timely if filed no later than **July 6, 2009**. This Response is accompanied by a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 and the corresponding fee. If additional fees are required, the Commissioner is hereby granted permission to deduct those fees from Deposit Account 02-4550.

Please amend the referenced application as follows:

**Amendments to the Claims** are reflected in the listing of claims, which begins on page 2.

**Remarks** begin on page 8, and ends on page 22.

Wanstall *et al.* (*Brit. J. Pharma.* 134:463-472, 2001) (10 pages) is submitted herewith as **Exhibit A**.